MOUNTAIN VIEW, Calif., Oct. 13 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com ), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received CE Mark approval for its RePneu Lung Volume Reduction Coil (LVRC) System to treat the later stages of emphysema.
The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by brochoscopically implanting Nitinol coils into the lungs to compress damaged tissue (lung volume reduction) and restore elastic recoil to the healthier lung tissue. This treatment offers a minimally invasive alternative to lung volume reduction surgery, and works independently of collateral ventilation.
The CE mark approval enables PneumRx to move forward with commercialization in Europe and other select markets. PneumRx intends to launch its RePneu LVRC System in Europe in the last quarter of 2010. PneumRx plans to continue its ongoing partnership with physicians through training and by offering novel products for the diagnosis and treatment of lung disease.
"We are thrilled to have achieved this important milestone, and look forward to introducing our RePneu LVRC to the European market to help improve the lives of so many people who are suffering from emphysema and have few other viable treatment options," said Erin McGurk, President and CEO of PneumRx, Inc. "We are extremely pleased with the significant improvements in pulmonary function tests, exercise tolerance, and quality of life experienced by our clinical trial patients, and expect to bring these same benefits to a broader population of emphysema patients with the commercialization of the RePneu LVRC System in Europe."
About PneumRx, Inc.
PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innov